Institute of Biomedical Research Corp. (MRES)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Operating profit | $m | -0 | -0 | ||||||
| Net profit | $m | -0 | -0 | -0 | 1 | -1 | -2 | -1 | - |
| EPS reported | $ | 0.00 | 0.00 | ||||||
| Operating cashflow per share | $ | 0.00 | 0.00 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | 0.00 | 0.00 | ||||||
| Free cash flow | $m | - | -0 | ||||||
| Net debt | $m | -0 | -0 | ||||||
| Book value equity | $m | -1 | -1 | ||||||
| Book value per share | $ | -0.00 | -0.00 | ||||||
| Number of shares | m | 2,884.04 | 2,884.04 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 1.56 | 2.75 | ||||||
| P/B LTM | x | -38.69 | -38.38 | ||||||
| P/S LTM | x | 807.56 | 894.97 | ||||||
| P/FCF LTM | x | 0.00 | -147.59 | ||||||
| EV/EBITDA LTM | x | -72.95 | -93.95 | ||||||
| EV/Sales LTM | x | 145.26 | 118.61 | ||||||
| Earnings Yield LTM | % | +64.10% | +36.36% | ||||||
| FCF Yield | % | 0.00% | -0.68% | ||||||
| Quality | |||||||||
| ROE | % | +425.53% | -1825.9% | ||||||
| ROIC | % | +61.79% | +61.79% | ||||||
| Operating margin | % | -11.06% | -11.06% | ||||||
| Gross margin | % | -5.42% | -5.42% | ||||||
| FCF/Sales | % | 0.00% | 0.00% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -44.01% | -49.48% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | - | - | ||||||
| Net Debt/EBITDA | x | 0.04 | 0.04 | ||||||
| EBIT/Net interest | x | -18.60 | -18.60 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | 0.02 | 0.03 | ||||||
| Gross debt/equity | x | -0.00 | -0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Institute of Biomedical Research Corp. (MRES) is a dedicated provider of comprehensive biomedical research and analytical services, operating both within Montenegro and across international markets. The company's core activities encompass fundamental scientific investigation and robust research and development initiatives for new biomedical products, advanced technologies, and innovative diagnostic methods, including experimental medical treatments. MRES also focuses on the creation of novel biomedical and food products. A significant part of its mandate involves regulatory oversight of industrial activities and their associated products, alongside scientific environmental monitoring. Furthermore, it delivers expert regulatory evaluation and certification services for a wide array of biomedical products. The institute also contributes to academic advancement through graduate research study programs in the biomedical and environmental fields. MRES manufactures and supplies a diverse range of healthcare devices. Its offerings include two-channel analog NMS units, various digital muscle stimulators, digital TENS devices, interferential therapy units, elite combination models, portable four-channel digital stimulators, and portable ultrasound equipment. The product portfolio also extends to photon red light devices for aesthetic applications, electric pain relief solutions, microcurrent electrical nerve stimulators, and high-volt pulsed stimulators. The company excels in the development and commercialization of specialized agents and products. This category features microbicidal agents, a variety of disinfectant solutions, and specialized medical supplies such as bandages tailored for severe burns. They also provide products for hard surface disinfection, microbicidal treatments for fabrics and textiles, insecticides (including those targeting bed bugs), microbicidal towels, and mouthwash. Key innovations include Purilair, an apparatus specifically designed for sterilizing compressed air within medical instruments, alongside colloidal silver and other electro-medical devices. A notable product is BioStim INF, which is engineered for reducing edema, alleviating pain, and delivering comprehensive therapeutic benefits. Beyond its product and research endeavors, MRES offers a broad spectrum of essential services. These include quality control, regulatory assistance, healthcare support, environmental analysis, building decontamination, and extensive environmental protection and management services. They are also a critical source for regulatory certifications of new biomedical products. Institute of Biomedical Research Corp. was established in 2010 and maintains its headquarters in Podgorica, Montenegro, with a representative office located in Montreal, Canada, facilitating its global operations.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Institute of Biomedical Research Corp. (MRES)
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Institute of Biomedical Research Corp. (MRES) is a dedicated provider of comprehensive biomedical research and analytical services, operating both within Montenegro and across international markets. The company's core activities encompass fundamental scientific investigation and robust research and development initiatives for new biomedical products, advanced technologies, and innovative diagnostic methods, including experimental medical treatments. MRES also focuses on the creation of novel biomedical and food products. A significant part of its mandate involves regulatory oversight of industrial activities and their associated products, alongside scientific environmental monitoring. Furthermore, it delivers expert regulatory evaluation and certification services for a wide array of biomedical products. The institute also contributes to academic advancement through graduate research study programs in the biomedical and environmental fields. MRES manufactures and supplies a diverse range of healthcare devices. Its offerings include two-channel analog NMS units, various digital muscle stimulators, digital TENS devices, interferential therapy units, elite combination models, portable four-channel digital stimulators, and portable ultrasound equipment. The product portfolio also extends to photon red light devices for aesthetic applications, electric pain relief solutions, microcurrent electrical nerve stimulators, and high-volt pulsed stimulators. The company excels in the development and commercialization of specialized agents and products. This category features microbicidal agents, a variety of disinfectant solutions, and specialized medical supplies such as bandages tailored for severe burns. They also provide products for hard surface disinfection, microbicidal treatments for fabrics and textiles, insecticides (including those targeting bed bugs), microbicidal towels, and mouthwash. Key innovations include Purilair, an apparatus specifically designed for sterilizing compressed air within medical instruments, alongside colloidal silver and other electro-medical devices. A notable product is BioStim INF, which is engineered for reducing edema, alleviating pain, and delivering comprehensive therapeutic benefits. Beyond its product and research endeavors, MRES offers a broad spectrum of essential services. These include quality control, regulatory assistance, healthcare support, environmental analysis, building decontamination, and extensive environmental protection and management services. They are also a critical source for regulatory certifications of new biomedical products. Institute of Biomedical Research Corp. was established in 2010 and maintains its headquarters in Podgorica, Montenegro, with a representative office located in Montreal, Canada, facilitating its global operations.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free